Innate Pharma SA (FR:IPH)
:IPH
Earnings Data
Report Date
Sep 10, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.29Last Year’s EPS
-0.25Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presents meaningful clinical and strategic progress across three prioritized programs (lacutamab Phase III clearance and regulatory designations, IPH4502 early activity and differentiated preclinical profile, and monalizumab PACIFIC-9 enrollment complete), and significant partnership upside with AstraZeneca. However, near-term financial constraints are material: low reported revenue (EUR 9M), operating expenses of EUR 63M, and a cash runway only through end-Q3 2026 create an urgent need for financing and execution on partnership or royalty deals. Clinical catalysts in H2 2026 (PACIFIC-9 readout, lacutamab Phase III initiation) are potentially value‑creating but also introduce binary risks. Overall, positives on R&D progress and partnership scale are substantially tempered by immediate funding and execution risks.Company Guidance
Lacutamab: Phase III Clearance and Regulatory Designations
FDA cleared the TELLOMAK-3 Phase III protocol for lacutamab in CTCL with planned initiation in H2 2026; lacutamab holds Breakthrough Therapy, Fast Track, PRIME and Orphan Drug designations and the Phase II data support a potential accelerated approval path in Sezary syndrome.
IPH4502: Early Clinical Activity and Differentiated Profile
First-in-human Phase I study of IPH4502 showing preliminary antitumor activity (including urothelial cancer post-enfortumab vedotin) with a favorable safety profile; MTD established and cohorts enriched at pharmacologically active doses; preclinical data show activity in low/heterogeneous Nectin-4 models supporting a differentiated TOPO1 ADC profile.
Monalizumab: Large Phase III Completed Enrollment
PACIFIC-9 Phase III (monalizumab + durvalumab arms) has completed enrollment (~999 patients randomized 1:1:1); primary endpoint PFS readout expected in H2 2026, representing a major near-term clinical catalyst.
IPH5201 / MATISSE: Positive Scientific Visibility
IPH5201 (anti-CD39) MATISSE Phase II interim analysis selected for oral presentation at AACR, increasing scientific visibility; program explores a mechanistically distinct approach upstream of CD73 with potential synergy with chemotherapy and durvalumab.
Partnerships with Significant Upside and Near-Term Cash Received
AstraZeneca deals provide material upside: monalizumab program worth up to $1.275B (already received $450M) and IPH5201 worth up to $885M (already received $60M); potential double-digit royalties and options to co-fund/co-promote in Europe.
Commercial Opportunity / Market Benchmarks for Lacutamab
Estimated U.S. incident patient pool: ~300/year for Sezary syndrome (prevalence ~1,000) and ~3,000/year for Mycosis Fungoides (prevalence ~12,000); company projects an initial Sezary market opportunity up to ~$150M expanding to >$500M across Sezary and MF in 2nd-line with upside over time; mogamulizumab benchmarked at ~$300M sales in 2025 (projected $350M in 2026).
Operational Discipline Reducing R&D Spend
R&D expenses decreased by 16% year-over-year to EUR 43.6M (R&D represented 73% of operating expenses), driven by study maturity and lower indirect R&D costs.
FR:IPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
FR:IPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 26, 2026 | €1.15 | €1.08 | -5.90% |
Sep 17, 2025 | €1.79 | €1.76 | -1.78% |
Mar 27, 2025 | €1.86 | €1.88 | +0.91% |
Sep 12, 2024 | €2.18 | €2.12 | -2.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Innate Pharma SA (FR:IPH) report earnings?
Innate Pharma SA (FR:IPH) is schdueled to report earning on Sep 10, 2026, Before Open (Confirmed).
What is Innate Pharma SA (FR:IPH) earnings time?
Innate Pharma SA (FR:IPH) earnings time is at Sep 10, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Innate Pharma SA stock?
The P/E ratio of Innate Pharma SA is N/A.
What is FR:IPH EPS forecast?
FR:IPH EPS forecast for the fiscal quarter 2026 (Q2) is -0.29.